Observational Cohort Study of Clinical Outcomes After Antiviral Therapy for Chronic Hepatitis C
Observational Cohort Study of Clinical Outcomes After Antiviral Therapy for Chronic Hepatitis C
This study was a clinical observational cohort study of two-way, non-intervention long-term
 dynamic follow-up. Enrolled in the Department of Liver Diseases, Beijing Ditan Hospital,
 Capital Medical University, with interferon combined with ribavirin (PR) antiviral therapy
 (PR treatment greater than or equal to 6 months) and/or direct acting antivirals (DAAs) In
 patients with chronic hepatitis C, the baseline, antiviral treatment and withdrawal follow-up
 data before the antiviral treatment were collected, and the patients were followed up for 3-6
 months. Clinical data such as clinical biochemistry, HCV RNA and serological markers
 (anti-HCV), AFP and liver imaging (liver ultrasound) were collected during the study period.
 At least 144 weeks of observation on the virological response and clinical outcome of
 anti-viral treatment of chronic hepatitis C, the main evaluation index of liver cancer and
 decompensated liver cirrhosis after stopping the drug, and exploring the antiviral treatment
 of patients Long-term virological response and clinical outcomes, clarifying their
 influencing factors.
This study was a clinical observational cohort study of two-way, non-intervention long-term
 dynamic follow-up. Enrolled in the Department of Liver Diseases, Beijing Ditan Hospital,
 Capital Medical University, with interferon combined with ribavirin (PR) antiviral therapy
 (PR treatment greater than or equal to 6 months) and/or direct acting antivirals (DAAs) In
 patients with chronic hepatitis C, the baseline, antiviral treatment and withdrawal follow-up
 data before the antiviral treatment were collected, and the patients were followed up for 3-6
 months. Clinical data such as clinical biochemistry, HCV RNA and serological markers
 (anti-HCV), AFP and liver imaging (liver ultrasound) were collected during the study period.
 At least 144 weeks of observation on the virological response and clinical outcome of
 anti-viral treatment of chronic hepatitis C, the main evaluation index of liver cancer and
 decompensated liver cirrhosis after stopping the drug, and exploring the antiviral treatment
 of patients Long-term virological response and clinical outcomes, clarifying their
 influencing factors.
Inclusion Criteria:

 -  Chronic hepatitis C patients treated with interferon plus ribavirin (PR) antiviral
 therapy (PR treatment greater than or equal to 6 months) and/or direct antiviral drugs
 (DAAs)

 Exclusion Criteria:

 -  Co-infected with hepatitis B virus or human immunodeficiency virus

 -  Had an autoimmune disease, liver tumour, or severe cardiac disease.